Member Info for Minnissage

Https://lnkd.in/eU6-GaEJ 

Not a deranp - a genuine question of anybody with more knowledge than myself

Board stated last raise would take them to q4 this year. Any intel on cash burn and likelihood of fundraise before any material contracts can be realised?

That’s the dilemma isn’t it right now Kuschall.

If CLX can deliver this term then revenue is nailed and warrants trigger giving access to a potential further 3.2m. Historic SP lows will be history and the boat missed. Glass half full or half empty. One thing is for sure some will say one thing whilst doing quite the opposite !

Excellent summation Tommy.

But for the historical overhang Val would command a much higher price based on current activity and asset base and people are beginning to see that and act accordingly.

Well Nom, under the old regime I doubt the company would still exist. Under Mark and the current BoD they are building a strategy and the lights are still on . Meaning that those of us still invested at least still have a percentage of something rather than 100% of nothing.

The value has to be in the build up of assets which from a drug discovery perspective I’m sure the current bod are working on. I for one am grateful that Val are still in the game.

Https://pmc.ncbi.nlm.nih.gov/articles/PMC7224248/

This link compares the tools currently out there including DosemeRx. It’s a long read but gives a view on competitor landscape and potential

Whilst I realise funding is dragging on sentiment taking the first steps to embedding your technology in a global platform is a pretty big deal

Reading the RNS Kodal have no influence here and are passengers. Otherwise they would be managing the visit not noting it. A lot of unknowns ……..

Before I get corrected I meant .54 lol

With the spread at 10% a lot of those sells are buys including the one I executed at .054

Macquarie will take $5m of the $22.5m fund raise equivalent to 4% of the company

There really is no future in the past so reliving it is utterly pointless. I’ve gone through two 100:1 consolidations and have the scars to prove it.

Before the BoD changes we were a dead duck. Not because of the science nor the intent. Rather because the BoD had become dysfunctional. The changes have given the company a renewed focus and impetus. Everyone, and especially the BoD know how critical H2 will be. The steps taken by Mark and his team thus far are significant and aimed at creating the value that shareholders expect. White rabbits we do not have. Only a will to focus on and execute a plan.

Many on here proclaimed 401 a bust yet it has been taken forward by Ambrose. Some will say the same about 201 yet the BoD have confirmed plans to continue to work with other parties on commercialisation just as they did with 401. Cytolytix is an exciting prospect and Stingray remains an active prospect. The lab is clearly not performing as originally envisaged but is saving Val significant sums on in-house research.

Why have I said all that ? Because I read all that had been exchanged on the BB over the weekend . Val remains as binary as it ever has. If you believe the BoD can carry it off then accumulate now ready for the news flow that must come if the warrants are to be triggered. If you don’t then your funds may be better utilised by exit and investment elsewhere. DYOR and make your assessment but don’t blame others for your own decisions.

Which I think he will uncanny. Move from dysfunctional previous BoD to here have been hard yards. Focus has to be on moving SP to point where warrants will trigger

Lots of optimism being expressed but beware a good old fashioned pump and dump

Funding is sitting in the warrants that trigger at .04. It’s reasonable to expect that we will see a news flow to trigger them now that the licence has been granted

I agree Uncanny. If a deal can be struck with the new consortium for 201, backed up by reformulation and revised patent, plus a positive outcome with Ambrose for 401 then things could look very different. The potential is there as is the cost management. I don’t believe this is dead yet Jim

I would expect the focus is on putting a deal together that gets the SP to the point where the warrants kick if which from memory is 1.3. So I am not surprised that you have added Nick

L2 suggests we won’t be here for long

Never underestimate the skills of a retired shareholder